TRAW

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Advances TXM and Ratutrelvir Amid $60M Financing

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Traws Pharma has successfully secured $60 million through a PIPE financing, enabling it to advance the clinical development of its lead drug tivoxavir marboxil (TXM) for influenza and ratutrelvir for COVID-19, which recently showed strong Phase 2a results. This financing positions the company to effectively support its operations into early 2027 while recovering from significant prior losses. The near-term challenge trial for TXM is a key upcoming catalyst.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Traws raises $60M in PIPE financing for its TXM and COVID programs.</li><li>TXM is advancing to a Phase 2a human challenge trial for influenza.</li><li>Ratutrelvir shows promising Phase 2a results versus PAXLOVID for COVID-19.</li><li>Current cash can support operations into Q1 2027 with new financing.</li><li>Company achieved $9.2 million net income in 2025, recovering from prior loss.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Pfizer Inc. (PFE)</strong>: Competitor to ratutrelvir in the COVID-19 treatment market with PAXLOVID.</li><li><strong>hVIVO (HVO)</strong>: Will conduct TXM&#039;s challenge trial, influencing operational and trial success.</li><li><strong>BARDA</strong>: Traws is seeking engagement for TXM&#039;s inclusion in the U.S. stockpile.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it outlines significant business updates, financing strategies, and the advancement of key clinical trials, which are critical for TRAW&#039;s growth trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive results from the challenge trial could significantly boost TRAW&#039;s stock price.</li><li>FDA resolution on TXM&#039;s clinical hold may impact investor sentiment positively.</li><li>Strength in COVID pipeline could lead to increased investor confidence in company valuation.</li><li>Milestones from the PIPE financing could unlock additional capital and value.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Traws secured up to $60M in PIPE financing on April 15, 2026.</li><li>TXM&#039;s Phase 2a challenge trial expected to start in Q2 2026.</li><li>Ratutrelvir Topline Phase 2a data shows it has a differentiated profile versus PAXLOVID.</li><li>Company achieved a net income of $9.2 million for 2025, recovering from prior major losses.</li><li>As of December 31, 2025, Traws had $3.8 million in cash reserves.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>TRAW is an attractive buy ahead of the Challenge Trial for TXM, expected in Q2 2026.</p>
  </section>
</section>


<article>
    <h2>Traws Pharma Reports Full Year 2025 Results and Business Highlights</h2>
    <p>NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/TRAW">TRAW</a>), a clinical-stage biopharmaceutical company, has officially released its financial results for the year ended December 31, 2025, along with significant business developments. The company is pushing forward with its lead investigational program, tivoxavir marboxil (TXM), aimed at influenza prophylaxis and treatment, while also announcing a private investment in public equity (PIPE) financing valued at up to $60 million.</p>

    <h3>Financial Highlights and Future Outlook</h3>
    <p>Traws Pharma's recent PIPE financing, which includes an upfront gross amount of $10 million, is designed to provide operational support through Q1 2027. This fund will facilitate the completion of the anticipated Phase 2a single-dose human Challenge Trial for TXM, a once-monthly oral agent aimed at preventing influenza infections. Traws is well-positioned to achieve its goals, thanks to a combination of this new funding, existing cash reserves, and ongoing efforts to address regulatory matters.</p>

    <blockquote>
        <p><strong>Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma</strong> stated, "Traws has made substantial progress over the last year towards advancing our potential best-in-class influenza program. The capital from the recent private financing positions Traws to complete the Challenge Trial while preserving access to substantial additional capital as key milestones are achieved."</p>
    </blockquote>

    <h3>Conference Call and Webcast Information</h3>
    <ul>
        <li>Date: April 15, 2026</li>
        <li>Time: 4:30 PM ET</li>
        <li>Participant Dial-in (U.S.): 1-877-407-0789</li>
        <li>Participant Dial-in (International): 1-201-689-8562</li>
        <li>Webcast Access: <a href="https://viavid.webcasts.com/starthere.jsp?ei=1753283&amp;tp_key=2b2419c52e" rel="nofollow" target="_blank">Click Here</a></li>
    </ul>
    <p>A replay of the webcast will be available on the <a href="https://www.trawspharma.com/corporate-events-presentations" rel="nofollow" target="_blank">Investors section of the Traws website</a>.</p>

    <h3>Recent Highlights and Anticipated Milestones</h3>
    <h4>$60 Million Private Financing</h4>
    <p>On April 15, 2026, Traws Pharma announced a PIPE financing offering up to $60 million. This includes:</p>
    <ul>
        <li>An initial $10 million in gross proceeds upon closing.</li>
        <li>Milestone-based and three-year warrants that could generate nearly $50 million in additional funding.</li>
        <li>The financing consists of the sale of 5,982,919 common shares at $1.6730 per share.</li>
    </ul>

    <h4>Key Financing Terms</h4>
    <p>The terms of the financing include features such as:</p>
    <ul>
        <li>Series A warrant with an aggregate exercise price of $10 million upon MHRA approval of the challenge trial.</li>
        <li>Series B warrant with an aggregate exercise price of $10 million following shareholder approval and data release from the challenge trial.</li>
        <li>Series C common warrants enabling additional gross proceeds of $30 million upon full exercise.</li>
    </ul>

    <h3>Investigational Programs: Tivoxavir Marboxil (TXM)</h3>
    <p>The main focus of Traws Pharma, represented by the stock symbol TRAW, is the investigational program for TXM. This product has the potential to become a <strong>best-in-class once-monthly prophylactic treatment</strong> for seasonal and pandemic flu, representing a multi-billion dollar market opportunity.</p>

    <h4>Recent Developments</h4>
    <p>Preclinical studies indicate that the new TXM tablet formulation enhances protection against various influenza strains, supporting its use as a preventive treatment. The company is also in discussions with the Biomedical Advanced Research and Development Authority (BARDA) for US stockpiling consideration and aims to resolve the clinical hold currently in place by the U.S. Food and Drug Administration (FDA).</p>

    <h4>Next Steps</h4>
    <ul>
        <li><strong>Completion of Phase 1 Bridging Study:</strong> This study, underway in Australia, aims to confirm the new tablet formulation's efficacy and coverage.</li>
        <li><strong>MHRA Approval and Challenge Trial Initiation:</strong> Traws plans to conduct a single-dose challenge trial once MHRA approval is received, using services from hVIVO, a leading conducter of human challenge studies.</li>
    </ul>
</article>

Traws Pharma has successfully secured $60 million through a PIPE financing, enabling it to advance the clinical development of its lead drug tivoxavir marboxil (TXM) for influenza and ratutrelvir for COVID-19, which recently showed strong Phase 2a results. This financing positions the company to effectively support its operations into early 2027 while recovering from significant prior losses. The near-term challenge trial for TXM is a key upcoming catalyst.

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News